mirikizumab   Click here for help

GtoPdb Ligand ID: 9846

Synonyms: Antibody I [US9023358] | LY-3074828 | LY3074828 | mirikizumab-mrkz | Omvoh®
Approved drug Immunopharmacology Ligand
mirikizumab is an approved drug (Japan, EMA and FDA (2023))
Compound class: Antibody
Comment: Mirikizumab (LY-3074828) is a humanized monoclonal antibody against human IL-23A (IL-23p19) which is designed for the treatment of autoimmune diseases. It is one of the novel agents for immune-mediated inflammatory diseases discussed in Baker et al. (2018) [1]. The peptide sequences of mirikizumab heavy and light chains are 100% matches to sequences 9 and 10 of Antibody I that is claimed in patent US9023358 [2].
Immunopharmacology Comments
Mirikizumab binds to IL-23A. This action reduces IL-23-mediated activation of Th17 cells, and inhibits their release of pro-inflammatory cytokines and chemokines.
Immunopharmacology Disease
Disease X-Refs Comment References
Crohn's disease Disease Ontology: DOID:8778
OMIM: 266600
Orphanet: ORPHA206
Phase 2 clinical candidate for active CD- see NCT02891226.
Psoriasis Disease Ontology: DOID:8893
Phase 2 clinical candidate for moderate to severe plaque type psoriasis- see NCT02899988.
Ulcerative colitis Disease Ontology: DOID:8577
OMIM: 266600
Orphanet: ORPHA771
Approved drug for moderate to severe UC 3